Novo Nordisk to Cut Ozempic, Wegovy US List Prices Up to 50% in Major GLP-1 Reset

Novo Nordisk is preparing a major change to the U.S. pricing of its best-selling GLP-1 medicines. According to a Wall Street Journal report cited by Reuters, the Danish pharmaceutical company plans to reduce the U.S. list prices of Ozempic and Wegovy beginning January 1, 2027. The reported move would lower the list price of both medicines to approximately $675 per month, marking one of the most significant pricing adjustments since weight-loss drugs became mainstream.

The planned pricing update would cut Ozempic’s list price by about 34% and Wegovy’s by roughly 50%. Reuters also reported that Novo Nordisk intends to lower the list price of Rybelsus, its oral semaglutide treatment, creating a more consistent pricing structure across its GLP-1 portfolio.

Why Novo Nordisk Is Reducing List Prices

GLP-1 medicines have become some of the fastest-growing products in the pharmaceutical industry, helping millions of people manage type 2 diabetes and obesity. However, their high U.S. list prices have remained under scrutiny from lawmakers, employers, insurers and patient advocacy groups.

Although insurance companies often negotiate large rebates that lower the actual cost paid by health plans, many patients still face out-of-pocket expenses tied to the published list price. Reducing that figure could improve affordability for some people while simplifying pricing across the company’s product range.

Competition in the GLP-1 Market Is Increasing

Novo Nordisk and Eli Lilly continue to dominate the rapidly expanding GLP-1 market. Demand for weight-loss and diabetes medicines has outpaced manufacturing capacity over the past several years, but supply conditions have gradually improved as both companies expand production.

With product availability becoming less of a concern, pricing and insurance coverage are emerging as key competitive factors. A lower list price may strengthen Novo Nordisk’s position during negotiations with insurers and pharmacy benefit managers while encouraging broader access to treatment.

Potential Impact on Patients

The amount people pay for Ozempic or Wegovy depends on their insurance coverage, deductibles and pharmacy benefits. Patients whose cost-sharing is calculated using the official list price could benefit most from the reported reduction.

For employers evaluating whether to include obesity treatments in their health plans, lower list prices could improve the long-term financial outlook. At the same time, individuals with comprehensive insurance coverage may experience little immediate change if their plans already receive substantial rebates.

Pricing Changes Come as Policy Debate Continues

The reported decision arrives as prescription drug affordability remains a major issue in U.S. healthcare policy. Federal efforts to reduce medicine costs, including Medicare’s authority to negotiate prices for selected drugs, have increased pressure on pharmaceutical companies to reassess long-term pricing strategies.

While Ozempic and Wegovy are not currently included in Medicare’s negotiated pricing program, their widespread use has placed GLP-1 medicines at the center of conversations about healthcare spending and insurance costs.

What Investors Will Be Watching

Investors will be closely monitoring whether lower list prices affect Novo Nordisk’s profit margins or help expand prescription volumes. Since obesity and diabetes treatments are commonly used over long periods, increased patient access could partly offset lower pricing through higher overall demand.

The broader pharmaceutical industry will also watch how competitors respond if lower published prices become more common across the GLP-1 market.

What Happens Next

Novo Nordisk has not publicly released detailed information about the reported pricing framework beyond the figures cited by Reuters. More details are expected before the planned implementation date in January 2027.

Reuters’ report on the planned pricing changes is available here.

The diabetes treatment sector continues to evolve rapidly, with companies pursuing new growth strategies, including MiniMed’s planned Nasdaq IPO following Medtronic’s diabetes business spin-off.